Monica Moreno, MD
Endocrinology, Diabetes & Metabolism · St George, UTNPI 1669679379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 317 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$992
- Amgen$513
- Lilly USA, LLC$397
- Dexcom, Inc.$242
- Insulet Corporation$209
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,14298%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 77 | $1,058 |
| Abbott | 87 | $992 |
| Amgen(2 entities) | 15 | $513 |
| Lilly USA, LLC | 27 | $397 |
| Dexcom, Inc. | 10 | $242 |
| Insulet Corporation | 8 | $209 |
| Pfizer | 10 | $186 |
| Boehringer Ingelheim | 8 | $136 |
| Novartis | 5 | $127 |
| BETA Bionics, Inc. | 8 | $123 |
| Chiesi USA, Inc. | 5 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $99 |
| AstraZeneca(2 entities) | 5 | $96 |
| Radius Health, Inc. | 6 | $95 |
| Sequel Med Tech, LLC | 3 | $82 |
| AbbVie | 4 | $71 |
| Amryt Pharma Holdings Ltd | 4 | $71 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| Neurocrine Biosciences, Inc. | 2 | $66 |
| Merck | 1 | $64 |
| Medtronic(2 entities) | 4 | $61 |
| IBSA Pharma Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Johnson & Johnson | 1 | $52 |
| Tandem Diabetes Care, Inc. | 3 | $44 |
| GRT US Holding, Inc. | 2 | $32 |
| Bayer | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$233
- DEXCOM G7 GSS (161)$125
- Ozempic$107
How this compares
$5,253 in reported general payments places this provider in the 60th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 239 | $315,443 |
| OzempicSemaglutide | 166 | $245,596 |
| TrulicityDulaglutide | 186 | $229,496 |
| JardianceEmpagliflozin | 78 | $117,827 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $71,615 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $62,883 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $51,883 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $45,936 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $40,852 |
| Novolog FlexpenInsulin Aspart | 88 | $30,856 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $30,660 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $26,460 |
| TradjentaLinagliptin | 19 | $24,866 |
| WegovySemaglutide | 15 | $23,677 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $22,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $397 | $551,427442 claims |
| Novo NordiskOzempic, Wegovy, Fiasp, Novolog | $1,058 | $286,488204 claims |
| Boehringer IngelheimJardiance, Tradjenta | $136 | $142,69397 claims |
| AstraZenecaFarxiga | $96 | $20,44416 claims |
| AbbVieSynthroid | $71 | $10,665107 claims |
| PfizerPremarin | $186 | $4,58615 claims |
| IBSA Pharma Inc.Tirosint | $58 | $3,01213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in St George
- Priya KrishnamurthySt George$22K
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Vishnu SundareshSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.